EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients

Maria Francisca Moraes-Fontes, Jocelyne Demengeot, António Coutinho

Journal of Clinical Immunology · 2025-12 · 45 (1)

DOI: 10.1007/s10875-025-01929-4 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Immunology, online erschienen am 01.10.2025. Verfasst von Maria Francisca Moraes-Fontes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fundação Champalimaud, Avenida Brasília, Lisboa, Portugal. francisca.fontes@fundacaochampalimaud.pt. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmune Checkpoint InhibitorsImmunotherapyT-Lymphocytes, RegulatoryGenetic Diseases, X-LinkedHumansMaleForkhead Transcription FactorsAutoimmune DiseasesFemaleImmune System DiseasesAdultDiabetes Mellitus, Type 1Diarrhea

Stichwörter der Autor:innen

Cancer immunotherapyCheck-point inhibitorsIPEXImmune-related adverse eventsRegulatory T cells

Substanzen

Immune Checkpoint InhibitorsForkhead Transcription FactorsFOXP3 protein, human

Autor:innen und Institutionen

  • Fundação Champalimaud, Avenida Brasília, Lisboa, Portugal. francisca.fontes@fundacaochampalimaud.pt.
  • Instituto Gulbenkian de Ciência, Oeiras, Portugal.
  • Fundação Champalimaud, Avenida Brasília, Lisboa, Portugal.

Zitieren

APA

Moraes-Fontes, M. F., Demengeot, J., & Coutinho, A. (2025). The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients. Journal of Clinical Immunology, 45(1). https://doi.org/10.1007/s10875-025-01929-4

Vancouver

Moraes-Fontes MF, Demengeot J, Coutinho A. The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients. Journal of Clinical Immunology. 2025;45(1). doi:10.1007/s10875-025-01929-4

BibTeX
@article{MoraesFontes2025,
  author = {Moraes-Fontes, Maria Francisca and Demengeot, Jocelyne and Coutinho, António},
  title = {The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients},
  journal = {Journal of Clinical Immunology},
  year = {2025},
  volume = {45},
  number = {1},
  doi = {10.1007/s10875-025-01929-4}
}
Kostenlos starten →